Shridar Ganesan, MD, PhD, discusses the current limitations and advantages of leveraging circulating-tumor DNA to detect minimal residual disease in patients with cancer, as well as how ctDNA assays may address mechanisms of resistance in clinical practice.
Investigators from Rutgers Cancer Institute of New Jersey, New Jersey's only National Cancer Institute- Designated Comprehensive Cancer Center, led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable (MSI) tumors.
E-Mail
IMAGE: Lance Liotta, MD, PhD, study PI, and George Mason University College of Science CAPMM co-founder and co-director. view more
Credit: Evan Cantwell, George Mason University
A George Mason University and Rutgers Cancer Institute of New Jersey collaboration received the U.S. Army s Breast Cancer Research Program (BCRP) Breakthrough Award to quickly confirm if an identified HER2 biomarker can indicate success likelihood of personalized breast cancer treatments.
George Mason University s College of Science announced an exciting $1.33 million collaboration with Rutgers Cancer Institute of New Jersey and Mason s Center for Applied Proteomics and Molecular Medicine (CAPMM) which taps cancer research diagnostics and treatment strengths within the medical facilities and CAP/CLIA laboratory respectively of the two regional powerhouses.